 That's a really good question. At the moment, Gilead is charging more than $42,000 per year for linacapavir to patients in the United States who are receiving it as treatment. If that's the price that it's set at as a prevention tool in Sub-Saharan Africa or other countries in the Global South, then it's a non-starter. Those countries just aren't going to be able to afford it.